Diane Schwarz
Adult Health · Newport Beach, CANPI 1548558554
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.5% of the total across 213 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AbbVie at 24.1% of the total. Reporting peaked in 2022 at $1,648 and has fallen 61.4% since, to $637 in 2025. Among adult health clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 213 payments — averaging $24.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$572
- GSK$567
- Lilly USA, LLC$558
- Novartis$420
- Johnson & Johnson$338
- plus $2K from 14 others
What the payments were for
- Consulting fees$751%
- Travel & lodging$20%
- Food & beverage$5,05797%
- Education$1052%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 58 | $1,261 |
| Amgen(2 entities) | 22 | $572 |
| GSK | 19 | $567 |
| Lilly USA, LLC | 24 | $558 |
| Novartis | 22 | $420 |
| Johnson & Johnson | 16 | $338 |
| AstraZeneca(2 entities) | 5 | $222 |
| UCB, Inc. | 8 | $203 |
| Boehringer Ingelheim | 7 | $203 |
| Mallinckrodt Hospital Products Inc. | 4 | $186 |
| Octapharma USA, Inc. | 4 | $148 |
| Organon | 9 | $141 |
| Sobi, Inc | 3 | $108 |
| Cardinal Health 110 LLC | 1 | $75 |
| Pfizer | 3 | $58 |
| Sanofi | 2 | $51 |
| Aurinia Pharma U.S., Inc. | 2 | $46 |
| Radius Health, Inc. | 2 | $39 |
| Kyowa Kirin, Inc. | 1 | $28 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,239 in reported general payments places this provider in the 90th percentile of 785 adult health providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 39 | $272,283 |
| Orencia ClickjectAbatacept | 17 | $93,271 |
| Enbrel SureclickEtanercept | 11 | $78,556 |
| KevzaraSarilumab | 12 | $51,075 |
| PlaquenilHydroxychloroquine Sulfate | 11 | $9,506 |
| MethotrexateMethotrexate Sodium | 104 | $2,763 |
| Hydroxychloroquine Sulfate | 64 | $2,407 |
| Sulfasalazine DrSulfasalazine | 42 | $2,281 |
| Leflunomide | 31 | $1,848 |
| Duloxetine Hcl | 22 | $542 |
| Allopurinol | 46 | $444 |
| Prednisone | 64 | $436 |
| Colchicine | 14 | $359 |
| Tramadol Hcl | 51 | $277 |
| Alendronate Sodium | 37 | $233 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SanofiKevzara | $51 | $51,07512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 785 adult health providers in California.
Other adult health in Newport Beach
- Michele WestendorfNewport Beach$30K
- Karolina FaysmanLos Angeles$1.1M
- Linda BuckLos Angeles$170K
- Naomi PesynaAnaheim$141K
- Stacy GrissenEncinitas$82K
- Kimberly PodsadaSan Diego$78K
- Brenda PatrickSan Leandro$68K
- Brittany PolizziEncinitas$35K
- Nancy NicolosiLaguna Woods$31K
- Lisa HinemanLos Angeles$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.